- Home
- HOTH vs SILO Comparison
HOTH vs SILO Comparison
Compare HOTH & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOTH
- SILO
- Stock Information
- Founded
- HOTH 2017
- SILO 2010
- Country
- HOTH United States
- SILO United States
- Employees
- HOTH N/A
- SILO N/A
- Industry
- HOTH Biotechnology: Pharmaceutical Preparations
- SILO Apparel
- Sector
- HOTH Health Care
- SILO Consumer Discretionary
- Exchange
- HOTH Nasdaq
- SILO Nasdaq
- Market Cap
- HOTH 5.8M
- SILO 4.7M
- IPO Year
- HOTH 2019
- SILO N/A
- Fundamental
- Price
- HOTH $0.81
- SILO $0.84
- Analyst Decision
- HOTH Strong Buy
- SILO
- Analyst Count
- HOTH 4
- SILO 0
- Target Price
- HOTH $4.75
- SILO N/A
- AVG Volume (30 Days)
- HOTH 1.2M
- SILO 596.1K
- Earning Date
- HOTH 12-24-2024
- SILO 11-12-2024
- Dividend Yield
- HOTH N/A
- SILO N/A
- EPS Growth
- HOTH N/A
- SILO N/A
- EPS
- HOTH N/A
- SILO N/A
- Revenue
- HOTH N/A
- SILO $72,102.00
- Revenue This Year
- HOTH N/A
- SILO $1.86
- Revenue Next Year
- HOTH N/A
- SILO N/A
- P/E Ratio
- HOTH N/A
- SILO N/A
- Revenue Growth
- HOTH N/A
- SILO N/A
- 52 Week Low
- HOTH $0.58
- SILO $0.77
- 52 Week High
- HOTH $1.73
- SILO $4.50
- Technical
- Relative Strength Index (RSI)
- HOTH 45.48
- SILO 49.42
- Support Level
- HOTH $0.82
- SILO $0.77
- Resistance Level
- HOTH $0.85
- SILO $0.98
- Average True Range (ATR)
- HOTH 0.04
- SILO 0.10
- MACD
- HOTH -0.00
- SILO 0.00
- Stochastic Oscillator
- HOTH 26.94
- SILO 58.94
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.